Aarti K. Bhatia

Oncology
333 Cedar St
New Haven, CT 06510

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.

Journal: Future oncology (London, England)
Published: October 15, 2025

Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study.

Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study.

Journal: Oral oncology
Published: October 09, 2025

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Journal: Cancer
Published: September 05, 2025

Redefining Systemic Therapy Timing in Nasopharyngeal Cancer-Before, During, or After Radiation.

Redefining Systemic Therapy Timing in Nasopharyngeal Cancer-Before, During, or After Radiation.

Journal: JAMA oncology
Published: July 24, 2025

Head and neck cancer - emerging targeted therapies.

Head and neck cancer - emerging targeted therapies.

Journal: Frontiers in oncology
Published: June 04, 2025

Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era.

Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era.

Journal: Frontiers in oncology
Published: February 15, 2025

Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Journal: Head & neck
Published: January 07, 2025

Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability.

Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability.

Journal: JAAD international
Published: May 30, 2023

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 28, 2023

Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.

Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.

Journal: Drugs
Published: January 03, 2023

Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer.

Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer.

Journal: Cancer journal (Sudbury, Mass.)
Published: September 27, 2022

Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.

Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases.

Journal: Ophthalmic plastic and reconstructive surgery
Published: May 03, 2022
Showing 1-12 of 27

Last Updated: 09/26/2026